OUR EXPERT NETWORK

• Structure-Guided siRNA Design: How Chemistry, Context, And Constraint Are Shaping The Next Phase Of RNAi Therapeutics

  As siRNA design matures, the next breakthroughs will depend on balancing chemical optimization, delivery challenges, and expanding beyond established design rules.

• Scaling RNA Therapeutics: Purification, LNP Formulation, And GMP Manufacturing (Pt. 2)

  Part 2 explores the downstream technologies that turn RNA into a therapeutic product, from impurity removal and LNP formulation to GMP infrastructure and scalable manufacturing.

• From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS Repair

  Exosomes are biological vesicles used for cellular communication that can overcome CNS barriers, delivering therapeutic cargo for CNS and optic nerve injuries.

• Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking

  RNAi therapeutics may help oncology move beyond single-target drugs by disrupting adaptive tumor survival networks driving resistance in solid tumors.

• What Makes An RNA Platform Investable? Lessons From The Last Wave Of Biotech Financing

  RNA investing has shifted from hype to scalability, forcing companies to prove manufacturability, delivery strength, and platform-wide value.